Track topics on Twitter Track topics that are important to you
Coaxial electrospinning, in which Poly (L-lactic acid-co-ε-caprolactone) (PLC) with different Lactic acid (LA) to caprolactone (CL) ratio (75:25 and 50:50) were employed to electrospin core-shell nanofibers which could mimic the native extracellular matrix for tissue engineering applications. Core-shell nanofibrous scaffolds of PLC (50:50)/BSA (426 ± 157 nm) and PLC (75:25)/BSA (427 ± 197 nm) were fabricated and model drug bovine serum albumin (BSA) was entrapped in the core layer. The morphology, core-shell structure and sustained release behaviors were evaluated by Scanning electron microscopy (SEM), transmission electron microscopy (TEM), inverted fluorescence microscopy, water contact angle test and in vitro release test, respectively. The effect of core-shell structure and shell layer materials on the variation tendency of mechanical characterization in dry and wet situation were also investigated by tensile testing. The in vitro biocompatibility of scaffolds were investigated by growing human mesenchymal stem cells (hMSCs) on scaffolds surface and the proliferation of cells were evaluated with Alamar Blue tests. In vitro cultivations of hMSCs showed that PLC (50:50)/BSA scaffolds supported a significantly higher proliferation rate of seeded cells than scaffolds prepared by polymer PLC (75:25)/BSA. Overall, the PLC core-shell nanofibers possessed potentially regulable mechanical properties useful for tissue engineering as well as sustained release potential for medical applications.
This article was published in the following journal.
Name: Journal of the mechanical behavior of biomedical materials
Cellulose nanocrystal (CNC)/poly(lactic acid) (PLA) in situ nanocomposite scaffolds were fabricated by in situ polymerization of lactic acid and CNC which was directly utilized as aqueous suspension, ...
Poly-L-lactic acid (PLLA) is a biodegradable synthetic polyester synthesized by polymerization or polycondensation. PLLA hydrolytically degrades into lactic acid, a biocompatible metabolic by-product,...
in vitro in vitro ± ± ± in vitro
To avoid severe exacerbations in the load of hepatitis B virus (HBV) as a consequence of discontinuous use of anti-HBV drugs, entecavir (ETV), the first-line anti-HBV drug, was primally formulated as ...
Tissue engineering and regenerative medicine rely extensively on biomaterial scaffolds to support cell adhesion, proliferation, and differentiation physically and chemically in vitro and in vivo. Chan...
Primary: Evaluate the degree of correction attainable with Poly-L-Lactic Acid(Sculptra) for the correction of hill and valley acne scarring Secondary: Document types and inc...
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial ...
This is a phase IV prospective, multicentre, single cohort, open-label clinical trial evaluating the efficacy and safety of Poly-L-lactic acid (Sculptra® Aesthetic) for the treatment of c...
This study will evaluates the emotional and functional benefits of Poly-L-Lactic Acid (Sculptra™), a cosmetic product used to fill defects of the skin. All participants will receive Scul...
All subjects will receive three, single-sided injections of PLLA, performed 1 month apart.
The mechanical property of material that determines its resistance to force. HARDNESS TESTS measure this property.
A species of gram-positive, rod-shaped LACTIC ACID bacteria that is frequently used as starter culture in SILAGE fermentation, sourdough, and lactic-acid-fermented types of beer and wine.
A poly(A) binding protein that is involved in promoting the extension of the poly A tails of MRNA. The protein requires a minimum of ten ADENOSINE nucleotides in order for binding to mRNA. Once bound it works in conjunction with CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR to stimulate the rate of poly A synthesis by POLY A POLYMERASE. Once poly-A tails reach around 250 nucleotides in length poly(A) binding protein II no longer stimulates POLYADENYLATION. Mutations within a GCG repeat region in the gene for poly(A) binding protein II have been shown to cause the disease MUSCULAR DYSTROPHY, OCULOPHARYNGEAL.
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as diabetes mellitus, leukemia, or liver failure.
The addition of a tail of polyadenylic acid (POLY A) to the 3' end of mRNA (RNA, MESSENGER). Polyadenylation involves recognizing the processing site signal, (AAUAAA), and cleaving of the mRNA to create a 3' OH terminal end to which poly A polymerase (POLYNUCLEOTIDE ADENYLYLTRANSFERASE) adds 60-200 adenylate residues. The 3' end processing of some messenger RNAs, such as histone mRNA, is carried out by a different process that does not include the addition of poly A as described here.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...